Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The field of renal cell cancer has undergone a significant resurgence. This book summarizes up-to-date research and innovative ideas for the future in this rapidly changing field, which encompasses medicine, surgery, radiation oncology, basic science, pathology, radiology, and supportive care. This book is aimed at the clinician or scientist who has an interest in renal cell cancer, whether they are academic or nonacademic. The book covers tumor biology, molecular biology, surgery techniques, radiation therapy, personal testimonies, and present and future treatments of the disease that are on the horizon. The goal was to produce a textbook that would act as an authoritative source for scientists and clinicians and interpret the field for trainees in surgery, medicine, radiation oncology, and pathology.

Renal cell carcinoma. --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Cancer --- Kidneys --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal Cell Cancer: Diagnosis and Therapy covers diagnostics, cancer research, molecular biology, immunology and clinical management. It provides an overview of new information in epidemiology, molecular and immunologic characteristics, and surgical therapy. The state-of-the-art reference work covering renal cell cancer in its full extent currently on the market, it presents every aspect on the topic, new data and techniques, with a special focus on the latest diagnostic tests, genetic counselling, surgery - including laparoscopy and minimally invasive therapies. Special topics are included, such as advanced disease, special situations, pain management, palliative care and follow-up. A significant part of the book deals with immunotherapy and the exciting new developments in molecular targeted therapy, including angiogenesis inhibitors, tyrosine kinase inhibitors and mTOR inhibitors, for patients with advanced renal cell carcinoma. Renal Cell Cancer: Diagnosis and Therapy is the reference work of choice on this topic for urologists and oncologists.

Renal cell carcinoma --- Treatment. --- Diagnosis. --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Cancer --- Kidneys --- Oncology  . --- Urology. --- Radiology, Medical. --- Oncology. --- Imaging / Radiology. --- Clinical radiology --- Radiology, Medical --- Radiology (Medicine) --- Medical physics --- Medicine --- Genitourinary organs --- Tumors --- Diseases --- Radiology. --- Radiological physics --- Physics --- Radiation

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal Cancer: Contemporary Management provides a state of the art overview of the major topics in the field of kidney cancer. The material has been collected from the most current evidence based resources to allow for the appropriate care of these patients. The sections of the book have been structured to give an overview of the major issues dealing with renal cell carcinoma and transitional cell carcinoma of the kidney. The text also reviews the new staging system, discusses familial syndromes of renal cell carcinoma, and provides new perspectives with regard to imaging and managing renal tumors. A valuable resource for physicians and researchers dealing with renal cancer, Renal Cancer: Contemporary Management provides a comprehensive summary of the field that will guide patient management and stimulate further clinical and basic science research efforts. .

Cancer -- Surgery. --- Kidney neoplasms. --- Kidneys -- Cancer -- Treatment. --- Urology. --- Kidneys --- Urologic Neoplasms --- Diagnostic Techniques and Procedures --- Adenocarcinoma --- Urogenital Neoplasms --- Carcinoma --- Diagnosis --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Neoplasms, Glandular and Epithelial --- Neoplasms by Site --- Neoplasms --- Neoplasms by Histologic Type --- Diseases --- Carcinoma, Renal Cell --- Kidney Neoplasms --- Neoplasm Staging --- Medicine --- Health & Biological Sciences --- Urology & Nephrology --- Treatment --- Cancer --- Renal cell carcinoma. --- Oncology. --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Medicine. --- Surgery. --- Surgical oncology. --- Medicine & Public Health. --- General Surgery. --- Surgical Oncology. --- Tumors --- Surgery, Primitive --- Genitourinary organs --- Oncologic surgery --- Oncological surgery --- Surgical oncology --- Excision --- Cancer Therapy. --- Treatment. --- Cancer therapy --- Cancer treatment --- Therapy

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This volume examines every major topic area in the modern era of renal carcinoma biology and treatment.   The unique and intricate genetics of this cancer are highly distinct from most other tumors, and the advances made in this cancer beyond VHL biology have been intrinsically driven by discoveries from familial renal cell carcinomas linked with newer large scale genomic efforts in sporadic disease.  These genetic findings fuel strategies to analyze and define sporadic tumors for greater accuracy in prognosis and prediction of response to therapy.   Additional topics include major new therapeutic strategies that harness these biological discoveries, in particular angiogenic, energy metabolism, chromatin remodeling, tumor microenvironment, and classical signaling pathways.   This text will bring all of these avenues of investigation together for readers interested in understanding the dynamics of this field in the last decade and anticipating a continued steep trajectory in advancements toward the cure of this disease in its many manifestations.

Carcinoma, Renal Cell. --- Kidney Neoplasms. --- Renal cell carcinoma. --- Renal cell carcinoma --- Urologic Neoplasms --- Drug Discovery --- Drug Therapy --- Adenocarcinoma --- Kidney Diseases --- Chemistry, Pharmaceutical --- Investigative Techniques --- Urologic Diseases --- Therapeutics --- Urogenital Neoplasms --- Carcinoma --- Neoplasms, Glandular and Epithelial --- Male Urogenital Diseases --- Female Urogenital Diseases --- Pharmacology --- Analytical, Diagnostic and Therapeutic Techniques and Equipment --- Neoplasms by Site --- Chemistry --- Female Urogenital Diseases and Pregnancy Complications --- Diseases --- Natural Science Disciplines --- Biological Science Disciplines --- Neoplasms --- Neoplasms by Histologic Type --- Disciplines and Occupations --- Kidney Neoplasms --- Carcinoma, Renal Cell --- Drug Design --- Drug Delivery Systems --- Medicine --- Health & Biological Sciences --- Oncology --- Cancer --- Treatment. --- Cancer therapy --- Cancer treatment --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Therapy --- Medicine. --- Cancer research. --- Pharmacology. --- Biomedicine. --- Cancer Research. --- Pharmacology/Toxicology. --- Kidneys --- Oncology. --- Toxicology. --- Chemicals --- Poisoning --- Poisons --- Tumors --- Toxicology --- Drug effects --- Medical pharmacology --- Medical sciences --- Chemotherapy --- Drugs --- Pharmacy --- Cancer research --- Physiological effect

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Renal cancer is a health problem of major concern worldwide. Although tyrosine kinase inhibitors and immune check-point blockade treatments, alone or in combination, are giving promising results, failures are quite frequent due to intratumor heterogeneity and to the acquisition of drug resistance. The spectrum of renal cell carcinoma subtypes is wide. Up to 70–80% of renal tumors are clear cell renal cell carcinomas, a clinically aggressive tumor subtype linked to VHL gene inactivation. Next in frequency, the papillary renal cell carcinoma category encompasses an intricate puzzle of classic and newly described entities with poorly defined limits, some of them pending definite clarification. Likewise, the chromophobe–oncocytoma duality, the so-called hybrid tumors and oncocytic neoplasms, remain to be well profiled. Finally, a growing list of very uncommon renal tumors linked to specific molecular signatures fulfill the current portrait of renal cell neoplasia. This Special Issue of Cancers regards RCC from very different perspectives, from the intimate basic mechanisms governing this disease to the clinical practice principles of their diagnoses and treatments. The interested reader will have the opportunity to contact with some of the most recent findings and will be updated with excellent reviews.

Renal cell carcinoma. --- Kidneys --- Cancer. --- Adenocarcinoma of kidney --- Clear cell carcinoma --- Grawitz tumor --- Grawitz's tumor --- Hypernephroid carcinoma --- Hypernephroma --- Renal adenocarcinoma --- Renal cell adenocarcinoma --- Cancer --- N-glycomapping --- n/a --- SMAD proteins --- patient survival --- pro-IL-1? --- survival prediction --- inflammation markers --- tumor migration --- prognostic factors --- practical approach --- circular RNAs in a clinico-genomic predictive model --- glycomarkers --- review --- nephrectomy --- uric acid --- VEGF inhibitors --- metabolic reprogramming --- collecting duct carcinoma --- curcumin --- metabolome profiling --- identification of circular RNAs --- IL-2 --- experimental validation of circular RNA --- Raf/MEK/ERK --- HOT --- PI3K/Akt/mTOR --- pentose phosphate pathway --- kidney cancer --- LOT --- mutation --- RCC --- polybromo-1 --- pale cell --- MMP-9 --- gene expression --- recurrence free survival --- chromosomal loss --- IL-1? --- chronic kidney disease --- glutathione transferase omega 2 --- label-free --- glutathione transferase omega 1 --- emerging entity --- copy number alteration --- FOXO3 --- predictive role --- tumor slice culture --- tyrosine kinase inhibitors --- PPP --- ESC --- CDKN1A expression --- metastasis --- PD-L1 --- diagnostic and prognostic markers --- EVI1 --- copy number loss --- RNA sequencing --- NK cells --- glutathione metabolism --- clear cell renal cell carcinoma --- renal cell cancer --- proliferation --- eosinophilic variant --- Xp11 translocation renal cell carcinoma --- prognosis --- invasion --- immune infiltration --- IL4R? --- FISH --- 11) translocation renal cell carcinoma --- tumor microenvironment --- metabolome --- hyperosmolality --- toxicity --- ALK --- drug sensitivity --- t(6 --- copy number analysis --- urine --- genetic association --- polymorphism --- solute carrier proteins --- kidney --- metastatic ccRCC --- molecular genetic features --- recurrence-free survival --- chromophobe renal cell carcinoma --- unclassified renal tumor --- overall survival --- mTOR inhibitors --- mTOR --- JAK2 --- von Hippel–Lindau --- miR-155-5p --- glycoproteomics --- PBRM1 --- miR-133b --- survival --- TFE3 --- TFEB --- oncocytic renal tumor --- immune checkpoint inhibitors --- biomarker --- MMP10 --- TCGA --- ghrelin --- EMT like --- checkpoint inhibitors --- MiT family translocation renal cell carcinoma --- gene signature --- sarcomatoid --- transforming growth factor beta --- clear cell Renal Cell Carcinoma --- tumor adhesion --- renal cancer --- unclassified renal cell carcinoma --- Papillary renal cell carcinoma (pRCC) --- miR-146a-5p --- renal cell --- everolimus --- integrins --- cytoreductive nephrectomy --- immunotherapy --- predictive factors --- immunohistochemistry --- MTA2 --- IL13R?1 --- targeted therapy --- intratumour heterogeneity --- aurora A --- TCA cycle --- AMP-activated protein kinases --- cancer-specific survival --- programmed death-ligand 1 --- efficacy --- renal cell carcinoma --- anaplastic lymphoma kinase rearrangement --- TFEB-amplified renal cell carcinoma --- statins --- cancer immunotherapy --- microRNA --- new entity --- proteome profiling --- von Hippel-Lindau